Cortisol is quietly wrecking your sleep, weight, and recovery - 22 trials point to the same fix
IngredientsFebruary 20256 min read

Cortisol is quietly wrecking your sleep, weight, and recovery - 22 trials point to the same fix.

You've felt it. The moment a stressful week starts affecting your sleep, your hunger, your patience. What you might not know is that the hormone orchestrating all of it - cortisol - can be measurably, reliably reduced. Not by meditating more. By choosing the right plant extract at the right dose, backed by two decades of clinical trials.

Withania somnifera has been used in Ayurvedic medicine for over 3,000 years. The modern clinical literature on it is, by supplement standards, unusually rigorous - there are now 22 published randomised controlled trials examining its effects on cortisol, stress, thyroid function, testosterone, and cognitive performance. The problem is that most of what is sold as "ashwagandha" bears almost no resemblance to what was tested in those trials.

The standardisation problem

Ashwagandha root powder is not a standardised ingredient. The concentration of active withanolides - the steroidal lactones responsible for the adaptogenic effects - varies by a factor of 10 to 20 between raw root preparations depending on soil, climate, harvest timing, and processing. A product containing 500 mg of unstandardised root powder may contain as little as 0.5–1% withanolides by mass.

KSM-66 is a full-spectrum root extract standardised to a minimum 5% withanolides by HPLC verification, developed by Ixoreal Biomed and used in the majority of the high-quality RCTs. Sensoril is a root-and-leaf extract standardised to 10% withanolides but uses a different extraction pathway that may alter the withanolide profile.

When we review the ashwagandha literature, we are - if we are being precise - reviewing the KSM-66 literature, because that is the extract used in the majority of the trials that produced positive results.

Cortisol: the mechanistic case

Ashwagandha's primary mechanism of action on cortisol appears to operate at the level of the hypothalamic-pituitary-adrenal (HPA) axis. Withanolides are believed to modulate GABA-A receptor activity - mimicking the inhibitory signalling that attenuates the stress response - and to directly inhibit the expression of heat shock proteins (Hsp70 and Hsp90) that support glucocorticoid receptor activity. The net effect is a blunting of cortisol output in response to psychological and physiological stressors.

The RCT evidence on cortisol

Chandrasekhar et al. (2012) in the Indian Journal of Psychological Medicine conducted the trial that established the benchmark. 64 adults with chronic stress were randomised to 300 mg KSM-66 twice daily (600 mg total) or placebo for 60 days. The ashwagandha group showed a 27.9% reduction in serum cortisol versus 7.9% in placebo. The PSS stress score fell by 44% versus 5.5%. This is the most-cited ashwagandha RCT and the one most brands reference - frequently without disclosing that the dose was 600 mg/day of KSM-66 specifically.

Pratte et al. (2014) used the same extract at 300 mg twice daily (600 mg total) in a naturopathic care setting and replicated the cortisol reduction findings with an additional signal on fatigue and concentration.

Salve et al. (2019) is notable because it used a lower dose (240 mg/day) and still showed significant cortisol reduction - suggesting the dose-response curve does not require 600 mg to be effective, though the magnitude of effect was smaller.

Across the 12 RCTs specifically examining cortisol as a primary or secondary endpoint, 11 reported statistically significant reductions. The outlier used a different, unstandardised extract.

Testosterone and physical performance

Wankhede et al. (2015) randomised 57 male subjects undergoing resistance training to 300 mg KSM-66 twice daily or placebo. The ashwagandha group showed significantly greater gains in muscle strength (bench press: +46.9 kg vs +26.4 kg), muscle recovery, and testosterone levels (+96.2 ng/dL vs +18.0 ng/dL) after 8 weeks. This is the primary trial cited for ashwagandha's effects on testosterone - and it used 600 mg/day KSM-66.

What the dose-response data shows

The threshold for measurable cortisol effects appears to be approximately 240–300 mg/day KSM-66. The range used in the majority of positive trials is 300–600 mg/day. There is no human trial data suggesting meaningful additional benefit above 600 mg/day. Our Balance formula contains 600 mg KSM-66 - the dose used in the highest-quality efficacy trials, from the extract specifically studied in those trials.

← Back to Journal